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Background: Interleukin-27 (IL-27) is a multifunctional cytokine with both pro-inflammatory and immunoregulatory
functions. At present, the role of IL-27 in pulmonary fibrosis remains unknown.
Methods: In this study, we observed the expression of IL-27/IL-27R in a mouse model of bleomycin (BLM)-induced
pulmonary fibrosis. We verified the role of IL-27 using hematoxylin and eosin as well as Masson’s staining methods and
measuring the content of hydroxyproline as well as collagen I and III. We assessed the differentiation of T lymphocytes
in the spleen and measured the concentration of cytokines in bronchoalveolar lavage fluid (BALF) and the expression
level of relevant proteins in the JAK/STAT and TGF-ß/Smad signaling pathways in lung tissue.
Results: Increased IL-27 expression in BLM-induced pulmonary fibrosis was noted. IL-27 treatment may alleviate
pulmonary fibrosis and increase the survival of mice. IL-27 inhibited the development of CD4+ IL-17+, CD4+ IL-4+ T,
and CD4+ Foxp3+ cells and the secretion of IL-17, IL-4, IL-6, and TGF-ß. IL-27 induced the production of CD4+ IL-10+
and CD4+ INF-γ+ T cells. IL-27 decreased the levels of phosphorylated STAT1, STAT3, STAT5, Smad1, and Smad3 but
increased the level of SOCS3.
Conclusions: This study demonstrates that IL-27 potentially attenuates BLM-induced pulmonary fibrosis by regulating
Th17 differentiation and cytokine secretion.
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Pulmonary fibrosis is a heterogeneous disease with mul-
tiple etiologies. Its primary pathological characteristics
include early diffuse fibrosing alveolitis followed by
pathologic hyperplasia of fibroblasts and collagen accu-
mulation replacing normal lung tissue [1]. Until recently,
its mechanism was not completely understood. Our previ-
ous studies explored the potential roles of Th17 lympho-
cytes and IL-17 in promoting pulmonary fibrosis [2,3].
Various factors regulate Th17 cell differentiation and influ-
ence pulmonary fibrosis. Recent evidence suggests that IL-
27, including EB13, an IL-12p40 homologous protein, and
p28 [4] have unique roles in T cell differentiation. IL-27
inhibits the development of pro-inflammatory Th17 cells* Correspondence: 2820582685@qq.com
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unless otherwise stated.by suppressing the expression of the Th17 transcription
factor RORγt, thereby preventing the production of inter-
leukin (IL)-17A and IL-17 F in naive T cells [5].
IL-27, an IL-6/IL-12 family cytokine, plays a crucial
role in immune regulation in the context of infection
and autoimmunity. IL-27 is produced by antigen-
presenting cells, such as monocytes, macrophages, and
dendritic cells [6,7]. IL-27 also plays an important role
in innate and adaptive immunity. In adaptive immunity,
IL-27 synergizes with IL-12 to induce IFN-γ production
by CD4, CD8 T cells and NK cells [8,9]. In innate im-
munity, IL-27 promotes the production of IL-1 and
TNFα in mast cells as well as IL-8 and IL-12 in mono-
cytes [10]. Kim and colleagues have indicated that the
TLR2-mediated production of IL-27 and chemokines by
respiratory epithelial cells promotes bleomycin (BLM)-in-
duced pulmonary fibrosis (BIPF) in mice, In addition, BIPF
was more severe in IL-17A−/− mice and in TLR2−/− mice
treated with an anti–IL-17 monoclonal antibody than inhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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conclusion regarding IL-17’s action in BIPF is inconsistent
with other research [12,13], and they did not explore the
direct mechanism of IL-27 in BIPF.
In the present study, we demonstrate the role of IL-27
in BIPF and provide a possible mechanism via immune




Male C57/BL mice (aged 7–8 weeks) were purchased from
Weitonglihua Company (Beijing). Mice used for experi-
ments were housed in a specific pathogen-free (SPF) room.
All procedures were performed in accordance with the
Declaration of Helsinki of the World Medical Association.
The protocols were also approved by the IRB/Ethics
Committee of Kunming Medical University. For the
pulmonary fibrosis model, 5 mg/kg BLM (Japan) was
dissolved in phosphate-buffered saline (PBS) buffer and
administered to the mice intratracheally. On days 3, 7, 14
and 28 following BLM injection, 3 mice were sacrificed,
and samples were collected. Either the mouse IL-27 re-
combinant protein (rmIL-27; 1 μg per mouse for seven
days) or anti-mouse IL-27 p28 functional grade purified
antibody (200 μg per mouse for one day; R&D System,
Minneapolis MN) was injected hypodermically. The mice
were sacrificed on days 7 and 28 after BLM or saline ad-
ministration (3 mice/group were randomly selected for
each time point). The mice were divided into four
groups: a control group with PBS buffer (n = 6); BLM
group (n = 12); BLM+ IL-27 group (n = 6) and BLM+ IL-27
antibody group (n = 6).
Tissue preparation and assessment of fibrosis
Whole lung tissues from the mice were dissected and
fixed for 1 day in 4% paraformaldehyde. Then, the sam-
ples were dehydrated and embedded in paraffin blocks.
Blocks of 6 μm thickness were cut and stained with
hematoxylin and eosin (HE) and Masson’s reagent
(Shanghai Bogoo Biotechnology. Co., Ltd) for the assess-
ment of pulmonary alveolitis and pulmonary fibrosis, re-
spectively. The histologic severity of the pulmonary
alveolitis and pulmonary fibrosis was scored as previ-
ously described [14].
Flow cytometry analysis
Lymphocytes were separated from spleen tissue samples
using lymphocyte separation medium (Solarbio Biotec,
Beijing). The cells were counted, and 5 × 105 to 1 × 106
cells were harvested in cold PBS. The cells were then re-
suspended in 100 μl PBS and incubated with 0.5 μg anti-
mouse CD3a PE, 0.25 μg anti-mouse CD4 FITC,
0.125 μg anti-mouse IFN gamma PE, 0.25 μg anti-mouseIL-4 FITC, 1 μg anti-mouse/rat Foxp3 FITC, 0.25 μg
anti-mouse IL-10 FITC or isotype control antibodies
(eBioscience, San Diego, CA). The cells were then
washed with cold PBS, and 104 cells per sample were an-
alyzed by flow cytometry (CyFlow, PARTEC).
Enzyme-linked immunosorbent assay (ELISA)
We collected bronchoalveolar lavage fluid (BALF) and
lung tissue samples from the various groups. The hy-
droxyproline (HYP) content of the lung tissue was mea-
sured using an ELISAs. The levels of IL-4, IL-10, IL-6,
IL-17, IFN gamma and TGF-β in the BALF were also
assessed using ELISAs. All ELISA kits were purchased
from CUSBIO Company and used according to the
manufacturer’s instructions.
Quantitative real-time PCR analysis
Total RNA was isolated from lung tissue using TRIzol
reagent (TAKARA). IL-27, IL-27R, COL1 and COL3
gene expression was measured using real-time polymer-
ase chain reaction (RT-PCR) performed on a Real-Time
PCR System (Applied Biosystems, ABI Prism 7300,
American) instrument with SYBRGreen (TAKARA),
starting with 1 ng of reverse-transcribed total RNA. PCR
was performed under the following conditions: 95°C for
5 min followed by 30 cycles of 95°C for 30 s and 60°C
for 30 s. The following oligonucleotide primers specific
for the mouse genes and β-actin were used: IL-27 p28,
5′-CTT CCT CGC TAC CAC ACT TCG-3′ (sense) and
5′-CCT CTT CCT CCT TGT CCT CCT-3′ (antisense);
IL-27R, 5′-GCT CTG CCC TGG TTT CTG TC-3′
(sense) and 5′-CTC CTT GAT GTA AGG TTG CCC-3′
(antisense); COL1, 5′-GGG TGA GAC AGG CGA ACA
AG-3′ (sense) and 5′-AAC CAG CAG AGC CAG
GGG-3′ (antisense); COL3, 5′-TGC CCA CAG CCT
TCT ACA CC-3′ (sense) and 5′-GCC ACC CAT TCC
TCC CAC-3′ (antisense); and β-actin, 5′-CGT GCG
TGA CAT CAA AGA GAA G-3′ (sense) and 5′-CCA
AGA AGG AAG GCT GGA AAA-3′ (antisense). The
amplification efficiency between the target and the refer-
ence control (GAPDH) was compared to use the delta
delta Ct (ΔΔCt) calculation.
Western blot analysis
Lung tissues were lysed in Tissue Protein Lysis Solution
(CWBIOTECH, Beijing). Protein from each sample was
loaded into a 10% sodium dodecyl sulfate (SDS)-poly-
acrylamide electrophoresis gel and transferred to a nitro-
cellulose membrane (Amersham Biosciences, Piscataway,
NJ). The blocked membrane was then incubated with
various antibodies. Antibodies against IL-27 (C-8),
COL1A2 (M-19), p-Stat1 (Tyr 701), p-Stat5 (Tyr 694/
Tyr 699), p-Smad3 (Ser 208), TGF-βR1 (V-22), p-Stat3
(B-7), and p-Smad1 (Ser 465) were purchased from
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SMAD1, STAT3, STAT5, STAT1, SMAD3, and β-actin
were purchased from Proteintech. The immunoreactive
bands were visualized with an enhanced chemilumines-
cent (ECL) reagent (Beyotime). The signal intensity of
the bands was quantified using Image J software.Statistical analysis
Data are expressed as the mean ± SD or median (range).
Statistical significance was determined using analysis of
variance (ANOVA), and the difference between two
groups was determined using the Student-Newman-Keuls
test. All tests were performed using SPSS 17.0 software. A
p-value < 0.05 was considered statistically significant.Results
IL-27/IL-27R expression increases in bleomycin-induced
pulmonary fibrosis
To explore the role of IL-27 in the pathogenesis of pul-
monary fibrosis, we assessed IL-27/IL-27R mRNA expres-
sion in BIPF using quantitative RT-PCR. IL-27/IL-27R
expression was the highest on day 7 of BIPF(1A, B). We
then treated these mice with either IL-27 or an IL-27 anti-
body and observed the level of IL-27/IL-27R 7 and 28 days
later (Figure 1B, C, D). Increased IL-27 was noted in the
BLM+ IL-27 group compared with the other groups. The
level of IL-27 at 28 days was increased compared with the
levels observed at 7 days for all groups except the control
group. These results indicate that IL-27 may be involved
in the formation of BIPF.Figure 1 IL-27/IL-27R expression increases in bleomycin-induced pulm
and 28 in the BLM and control groups. The expression of the CT values for real-
in the different groups. C, D. Western blot analysis; band intensities were mea
mean ± SEM. *p < 0.05, **p < 0.01.IL-27 attenuates bleomycin-induced pulmonary fibrosis
To verify the role of IL-27 in BIPF, the mice were di-
vided into four groups: a control group, BLM group,
BLM + IL-27 group, and BLM+ IL-27 antibody group.
HE staining revealed a disordered lung tissue structure;
the pulmonary interalveolar septa were thickened and
infiltrated by inflammatory cells, and a large number of al-
veoli were collapsed. These observations were consolidated
in the BLM group and most severe in the BLM+ IL-27
antibody group, whereas injected IL-27 alleviated the de-
gree of alveolitis. Based on Masson’s staining, wherein blue
stain represents the fibroblasts and collagen matrix, a simi-
lar trend was observed (Figure 2A, B).
In different tissues, hydroxyproline can act as a pri-
mary indicator of collagen metabolism. To more accur-
ately illustrate the severity of pulmonary fibrosis, we
measured the hydroxyproline content of the lung tissue
samples on days 7 and 28 in the four groups. We found
that the hydroxyproline content in the BLM group was
greater than that of the BLM + IL-27 group, whereas the
hydroxyproline content of the lung was significantly in-
creased in the group administered the IL-27 antibody
(Figure 2F). At the same time, we also measured the
levels of collagen I and III; the results were similar to
the hydroxyproline results (Figure 2C, D, E).
Over the course of the experiment, we noted the survival
rate of the mice and found that the BLM and BLM+ IL-27
antibody groups exhibited an increased mortality rate
compared with the other groups, with the BLM+ IL-27
antibody group exhibiting the highest survival rate. Sur-
prisingly, the survival of mice in the BLM+ IL-27 grouponary fibrosis. A. Real-time PCR for IL-27 and IL-27R, at days 3, 7, 14,
time PCR were normalized by 2-ΔΔct. B. IL-27 and IL-27R mRNA expression
sured using Image J. For each group, n = 3. Data are expressed as the
Figure 2 Exogenous IL-27 treatment can suppress BLM-induced pulmonary fibrosis. A. Hematoxylin and eosin (HE) staining (100x) and
Masson’s trichrome staining (100x) depicting the effects of exogenous IL-27 application on lung histological changes at days 7 and 28 in various treated
mice. B. The alveolitis and fibrosis scores for the lungs of mice in the different groups at days 7 and 28. Values are means ± SEM (n = 5). C, D, E. Real-time
PCR and Western blot analysis for COL1 and COL3, respectively, in the different groups. CT values for the real-time PCR were normalized by 2-ΔΔct. Western
band intensities were measured using Image J software. For each group, n = 3. F. The lung hydroxyproline content at days 7 and 28 for mice in the various
treatment groups. Hydroxyproline content was measured using an ELISA, n = 5. G. Survival rate of mice with BLM-induced pulmonary fibrosis.
The percentage of survival over time is presented, n = 5. Data are expressed as means ± SEM. *p < 0.05, **p < 0.01. A: control, B: BLM group, C:
BLM + IL-27 group, D: BLM + IL-27 antibody group.
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(Figure 2G). From the above results, we hypothesized that
IL-27 inhibits BIPF.
IL-27 regulates the differentiation of T lymphocytes
To explore the mechanisms by which IL-27 inhibits BIPF,
we evaluated T lymphocyte differentiation in spleen tis-
sues at day 28. Using intracellular fluorescence staining as
assessed by flow cytometry, we measured the CD4+ cells
also expressing Foxp3, IL-10, IL-17, IFN-γ, and IL-4.Compared with the control group, the BLM and BLM+
IL-27 antibody groups exhibited increased numbers of IL-
4-producing CD4+ cells, IL-10-producing CD4+ cells and
IL-17-producing CD4+ cells as well as a reduced number
of IFN-γ − producing CD4+ cells and Foxp3-producing
CD4+ cells. However, after the IL-27 treatment, these ex-
pression patterns were reversed with the exception of the
IL-10-producing CD4+ cells (Figure 3A, B). The above
findings suggest that IL-27 inhibits pulmonary fibrosis by
regulating T lymphocyte differentiation in the spleen.
Figure 3 The effect of IL-27 treatment on T lymphocyte differentiation in the spleen after 28 days. A. Representative figures from flow
cytometry analyses; CD4+ IL-4+, CD4+ IL-10+, CD4+ IL-17+, CD4+ Foxp3+ and CD4+ IFN-γ+ cells from the spleen were analyzed on day 28. B. Analyzed
data. Values are expressed as means ± SEM (n = 3). *p < 0.05, **p < 0.01.
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We also measured the concentrations of IL-4, IL-6, IL-10,
IL-17, IFN-γ and TGF-β in the BALF of mice at days 7
and 28 using an ELISA. In the BIPF model, IL-4, IL-10,
IL-17 and TGF-β were significantly increased compared
with the control group at days 7 and 28. IL-6 was also in-
creased at day 28. Conversely, IFN-γ was significantly de-
creased at days 7 and 28. These trends were exacerbated
following IL-27 antibody treatment. Conversely, IL-27
treatment reversed these trends (Figure 4A-F). Therefore,
we speculate that IL-27 may inhibit pulmonary fibrosis by
influencing the expression of inflammatory factors.
IL-27 regulates the JAK/STAT, TGF-ß/Smad signaling
pathway
To investigate the mechanism by which IL-27 acts in pul-
monary fibrosis, we determined JAK, STAT1, STAT3,
STAT5, and SOCS3 protein levels as well as STAT1,
STAT3, and STAT5 phosphorylation levels using Western
blot analysis. These results indicated that although the total
amounts of STAT1, STAT3, and STAT5 did not signifi-
cantly differ among the groups, BIPF increased the levels
of phosphorylated STAT1, STAT3, and STAT5. IL-27 treat-
ment decreased the expression of these phosphorylatedproteins. Conversely, the expression of SOCS3 was in-
creased in the BLM + IL-27 group and decreased in the
BLM group compared with the control group.
Previous ELISA results for TGF-β have suggested that
IL-27 inhibits TGF-β expression. To further assess the
relationship between IL-27 and the TGF-β signaling
pathway, we determined TGF-βR1, Smad1, and Smad3-
protein levels. We found that the levels of TGF-βR1 and
phosphorylated Smad1 and Smad3 were increased in the
BLM group compared with the control group. However,
IL-27 treatment resulted in decreased levels of these
proteins at days 7 and 28 (Figure 5A-D). These results
imply that IL-27 also inhibits activation of the JAK/
STAT and TGF-β/Smad signaling pathways in BIPF.
Discussion
In this study, our data demonstrate that IL-27 possesses
variable functions in pulmonary fibrosis. IL-27 may play
a role in diffuse alveolitis and fibroblast hyperplasia. To
explore the role of IL-27, we treated mice with BIPF
with either recombinant IL-27 protein or IL-27 anti-
bodies. The results verified that IL-27 alleviates pulmon-
ary fibrosis. IL-27 also enhances the survival of mice
with pulmonary fibrosis. Kim et al. proposed that re-
spiratory epithelial cells produce IL-27 and chemokines
Figure 4 The concentration of cytokines in the BALF of the different groups on days 7 and 28. The concentration (in pg/ml) of (A) IL-4;
(B) IL-6; (C) IL-10 ; (D) TGF-β; (E) IFN-γ; and (F) IL-17. Data are expressed as means ± SEM (n = 3). *p < 0.05, **p < 0.01.
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This result is inconsistent with our findings. The main
objective of their experiment was to identify the respira-
tory epithelial cells, rather than the immune cells, that
play a critical role in TLR2-mediated regulation of BLM-
induced tissue injury, which may explain the discrepan-
cies with our study.
IL-27 is a double-edged sword involved in offense and
defense [15]. IL-27 is a key cytokine that drives naive
cells into the Th1 subset during the initial step of differ-
entiation [16,17]. IL-27 also has an immunosuppressive
function that suppresses the production of inflammatory
cytokines. Several investigations have indicated that this
cytokine promotes the secretion of pro-inflammatory cy-
tokines by human monocytes [18] and has broad inhibi-
tory effects on Th1, Th2, Th17, and T-regulatory cells
[19-21]. Here, we explored the mechanism of IL-27 ac-
tion in BIPF. Our results indicate that IL-27 inhibited
the differentiation of Th1, Tr1, and Th17 and promoted
Treg and Th2 expression. IL-10 is most commonly rec-
ognized as an anti-inflammatory cytokine possessing im-
munosuppressive effects that are necessary for the
regulated resolution of pro-inflammation mechanisms.
Various research indicates that IL-10 over-expression in-
duces fibrosis partly through fibrocyte recruitment and
M2 macrophage activation, which likely involves a
CCL2/CCR2 axis [22]. In our study, although we did not
directly demonstrate the role of IL-10, we also observedthat IL-10 levels were elevated in BIPF at 7 and 28 days.
IL-27 treatment decreased IL-10 expression. Two im-
portant classes of Tregs within the CD4+ subset are the
CD4+ CD25+ Foxp3+ Tregs and the T regulatory type 1
(Tr1) cells [23]. Tr1 cells are CD4+ T lymphocytes de-
fined by their ability to produce IL-10 and suppress
helper T cells. We found that the expression of CD4+
CD25+ Foxp3+ Tregs was inhibited, whereas the number
of CD4+ IL-10+ T cells was increased in BIPF. IL-27
treatment changed these results.
In the BIPF model, we observed elevated levels of
TGF- β and IL-6, which is consistent with other reports
[24]. In mice, TGF-β and IL-6 or TGF-β and IL-21 in-
duce the differentiation of naive T cells toward the Th17
phenotype [25]. The role of Th17 cells and their secre-
tion of IL-17 (IL-17A) in pulmonary fibrosis has been
previously demonstrated by our group as well as others
[2,3,12,26]. In this experiment, our results indicate that
IL-27 attenuates pulmonary fibrosis by regulating T cell
differentiation and the secretion of IL-17 and other
cytokines.
Research has demonstrated that the JAK/STAT signal-
ing pathway is involved in pulmonary fibrosis [27].
IL-27 also activates the STAT1, STAT3, and STAT6
transcription factors. The activation of STAT1 and
STAT3 by IL-27 has been described in T cells, mono-
cytes, and keratinocytes [28,29]. However, this study is
the first to report that IL-27 suppresses STAT1 and
Figure 5 The expression of JAK/STAT and TGF-β/Smad signaling pathway-related proteins in the lung tissues of the different groups
on days 7 and 28. A. Western blots of JAK/STAT signaling pathway-related proteins: JAK, STAT1, STAT3, STAT5, SOCS3, and phosphorylated
STAT1, STAT3, and STAT5. B. A histogram of the relative gray values shown in A. C. Western blots for the TGF-β/Smad signaling pathway-related
proteins: Smad1, Smad3, TGF-βR1 and phosphorylated Smad1 and Smad3. D. A histogram of the relative gray values shown in C. Data are
expressed as means ± SEM (n = 3). *p < 0.05, **p < 0.01.
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detailed mechanism underlying IL-27’s effect on the
JAK/STAT3 signaling pathway remains unclear. Dysreg-
ulated SOCS3 activity may STAT3 signal transduction
in fibroblasts/myofibroblasts in idiopathic pulmonary fi-
brosis (IPF). The activity of SOCS3 was suppressed in
BIPF, an effect that was reversed by IL-27. The TGF-β/
SMAD signaling pathway could also mediate fibrosis via
the mechanism of the epithelial-mesenchymal transition
(EMT) [30]. Therefore, we also identified whether IL-27
influences the TGF-β signaling pathway in BIPF, but a
detailed mechanism will require further investigation.Conclusion
In summary, we verified that IL-27 is involved in BIPF.
In addition, IL-27 potentially inhibits the pulmonary fi-
brosis by regulating T cell differentiation and the secre-
tion of IL-17 and other cytokines and suppressing the
JAK/STAT and TGFβ1/SMAD signaling pathways. These
results have important implications for the treatment of
pulmonary fibrosis.Abbreviations
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